Last reviewed · How we verify
pegol-Sihematide
Pegol-sihematide is a long-acting erythropoiesis-stimulating agent that promotes red blood cell production.
Pegol-sihematide is a long-acting erythropoiesis-stimulating agent that promotes red blood cell production. Used for Anemia associated with chronic kidney disease (CKD).
At a glance
| Generic name | pegol-Sihematide |
|---|---|
| Also known as | HS-20039, EPO-018B |
| Sponsor | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| Drug class | Erythropoiesis-stimulating agent |
| Target | Erythropoietin receptor |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
It works by mimicking the action of endogenous erythropoietin, which binds to the erythropoietin receptor on bone marrow cells, stimulating the differentiation and proliferation of red blood cell precursors.
Approved indications
- Anemia associated with chronic kidney disease (CKD)
Common side effects
- Hypertension
Key clinical trials
- Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis (PHASE3)
- Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With NDD-CKD (PHASE3)
- Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes (PHASE1)
- Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis (PHASE2)
- Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With Chronic Kidney Diseases Not on Dialysis (PHASE2)
- Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With ERSD Receiving Maintenance Hemodialysis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pegol-Sihematide CI brief — competitive landscape report
- pegol-Sihematide updates RSS · CI watch RSS
- Jiangsu Hansoh Pharmaceutical Co., Ltd. portfolio CI